CliffBio
small molecule

CUBICIN RF

DAPTOMYCIN

Loss of exclusivityNovember 2030latest FDA-listed patent expiry
CompanyCubist Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameCUBICIN RF
Active ingredientDAPTOMYCIN
Strength500MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formPOWDER
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalJuly 2016
Marketing statusDISCN

Listed patents

PatentExpiresType
9138456November 2030product

More from Cubist Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

CUBICIN RF patent cliff — loss of exclusivity November 2030 | CliffBio